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The innate immune system must recognize and
rapidly respond to microbial pathogens, providing a
first line of host defense. This is accomplished
through an array of pattern recognition receptors
(PRRs) that reside in specific subcellular compart-
ments and can bind pathogen-associated molecular
patterns. PRRs also recognize self-molecules that are
released after cell damage or death, known as danger-
associated molecular patterns, which can be actively
transported across cell membranes. The activation of
PRRs leads to host defense pathways in infectious
diseases, but can also contribute to tissue injury in
autoimmune diseases. The identification of these
pathways has provided new insight into mechanisms
of vaccination and holds promise for developing
better vaccines. Finally, the identification of PRRs,
their ligands, and signaling pathways provides an
opportunity for developing new immunotherapeutic
approaches to skin conditions in which activation of
the innate immune response contributes to disease
pathogenesis.
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The current model of innate immunity derives from the
seminal observations of Metchnikoff (Metchnikoff, 1884;
Modlin and Cheng, 2004). By studying starfish larvae, he
realized that mobile cells might serve in the host’s defense
against microbial pathogens. In 1884, Metchnikoff demon-
strated that cells of the water flea Daphnia, which he termed
phagocytes, were attracted to and engulfed spores of a yeast-
like fungus. He wrote that ‘‘the spores which reached the
body cavity are attacked by blood cells, and- probably
through some sort of secretion- are killed and destroyed’’.
Thus, Metchnikoff had described the direct functions of
the innate immune system: (1) rapid detection of microbes,
(2) phagocytosis, and (3) antimicrobial activity. The phago-
cytic function of the innate immune system also contributes
to tissue homeostasis, e.g., in clearing toxic metabolites, dead
cells, and debris, as well as in regulating wound healing.
The contemporary view of the innate immune system is
based on Metchnikoff’s model. The direct functions of the
innate immune system provide a rapid first line of defense
against microbial pathogens. However, the innate immune
system by itself may not be sufficient to eliminate many
microbial pathogens. Ultimately, the adaptive immune
system, composed of T and B cell, and although slower to
develop than the innate immune response, clears the
microbial invader. The innate and adaptive immune
responses are linked, as the innate immune response has an
indirect function in host immunity, an instructive role in
stimulating adaptive T- and B-cell responses. Conversely, the
adaptive immune response can activate cells of the innate
immune system.
It would take over 100 years after Metchnikoff’s descrip-
tion of innate immunity for immunologists to discover the
mechanisms by which cells of the innate immune system
could rapidly recognize microbial invaders and subsequently
destroy them. Improvements in light microscopy provided
Metchnikoff with the necessary scientific tool to discover
innate immunity. In 1868, the microscope allowed Langer-
hans (1868) to visualize cells with a dendritic morphology in
the epidermis. These cells, known as ‘‘Langerhans cells’’, are
now known to be an important part of the skin immune
system.
In 1873, Hansen (1874) used microscopy to discover the
first human pathogen, Mycobacterium leprae, the cause of
leprosy. Fehleisen (1883) identified and cultured Streptococ-
cus pyogenes as the causative agent of erysipelas. Around
this time, several investigators noted that the occurrence
of erysipelas in cancer patients sometimes resulted in the
regression or remission of the tumor, including Busch (1866),
Fehleisen (1883), and the Russian writer and physician Anton
Chekov (Gresser, 1987). In addition, patients with various
malignancies were inoculated with ‘‘erysipelas’’ and shrink-
age of the tumor was noted (Fehleisen, 1883). Coley (1891)
continued these studies, and reported that in patients with
sarcoma there was regression of the tumor upon contraction
of erysipelas. Coley directly inoculated 10 patients with
various sarcomas with a bacterial culture derived from
erysipelas lesions, as well as the toxins from these cultures,
resulting in marked regression of some tumors. These
‘‘Coley’s toxins’’ were a mixture of S. pyogenes and Serratia
marcescens. Coley is frequently labeled as the ‘‘father of
immunotherapy’’ in recognition of his work. It is also worth
considering why a skin disease, erysipelas, was identified as a
potential mechanism of augmenting antitumor immunity.
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Clearly, the skin is readily observable and accessible,
and thus it was more likely that an exact clinical diagnosis
based on morphology could be made, and that specimens
could be readily obtained for microbiological identification
or immunotherapy. It is therefore no accident that some of the
early breakthroughs in microbiology and immunotherapy
came from the study of skin diseases such as leprosy and
erysipelas.
As scientists were trying to improve vaccines, they noted
that an intercurrent infection enhanced efficacy. Lewis and
Loomis (1924) ‘‘were led by an accidental occurrence to
carry through an experiment designed to show whether a
preexisting tuberculosis affected the production of antibody
for an antigen unrelated to the tubercle bacillus. The result
was definite, showing a decided increase in anti-sheep
amboceptor production by tuberculous guinea pigs.’’ They
called this ability of tuberculosis infection to increase anti-
sheep erythrocyte antibody production ‘‘allergic irritability’’.
In modern immunology, we describe this as an adjuvant, an
agent that when added to a vaccine would augment the
immune response to the target antigen.
The term adjuvant, from a Latin word meaning ‘to help’,
was coined in the 1920s by Gason Ramon, a veterinarian at
the Pasteur Institute (Pollack, 2009). He found that horses
immunized with diphtheria toxoid have a stronger response if
they developed an abscess at the inoculation site, and that
adjuvant activity was obtained by the addition of substances
such as bread crumbs or tapioca to the vaccine (Ramon,
1925, 1926). At the same time, aluminum salts were used to
precipitate and purify toxins, as well as in immunization
protocols. Importantly, the efficacy of a diphtheria toxoid
vaccine was improved by the addition of alum (Glenny et al.,
1926), which subsequently became a major adjuvant in
vaccines against infections in humans. In 1956, Freund
developed what would become the standard adjuvants for
vaccines in animal studies. Freund’s complete adjuvant uses
inactivated mycobacteria as a component. Subsequently, the
immunotherapeutic potential of the live mycobacterium
Bacillus Calmette-Guerin was explored in bladder cancer
(Morales et al., 1976) and melanoma (Morton et al., 1970).
For over a century, immunologists used bacterial products
in vaccines, with the knowledge that bacterial products had
special properties that could be harnessed in preventing and
treating disease, yet unaware of the mechanisms involved.
Discovery of the molecular mechanisms of innate immunity
and how adjuvants work would require over 100 years of
scientific and technical progress in a variety of disciplines:
cell biology, biochemistry, genetics, and high-speed comput-
ing. Innate immunity was ignored, but not forgotten; it was
not understood, but it was induced as part of vaccines.
Janeway (1989) advanced our thinking about the mam-
malian innate immune system by confronting what had been
ignored, asking ‘‘Why do we need to use adjuvants’’. It was
necessary to add adjuvants to vaccines in order to induce
robust immune responses to antigen. Janeway called this ‘‘the
immunologists dirty little secret’’ (Janeway, 1989). He further
reasoned that the adaptive immune response required two
signals for activation: ligation of the specific receptor on the
surface of a T or B cell by the antigen, but also a second
signal derived from another cell, the antigen-presenting cell,
later identified as costimulatory molecules (Janeway, 1989).
Janeway hypothesized that the capacity of antigen-presenting
cells to elicit an adaptive response was induced by a
distinctive recognition event involving evolutionarily primi-
tive receptors, enhancing antigen presentation function.
Janeway’s group gained insight from the study of innate
immunity in Drosophila, implicating the Toll protein in
recognition of foreign microbes and in activating host
defense. They discovered that triggering of a human homolog
of the Drosophila Toll protein, Toll-like receptor 4 (TLR4), on
innate immune cells, upregulated costimulatory molecule
expression and cytokine release required for T-cell activation
(Medzhitov et al., 1997). These data indicated that activation
of TLRs on cells of the innate immune system could instruct
the adaptive immune response.
The discovery that TLRs could trigger innate immune
responses raised the possibility that TLRs mediated recogni-
tion of microbial ligands. It was known that the innate
immune system detected microbes using pattern recognition
receptors (PRRs), which recognized biochemical patterns
expressed by groups of microbes, termed pathogen-asso-
ciated molecular patterns. Nevertheless, up until that time,
many of the identified PRRs had no known intracellular
signaling capacity. TLRs were logical candidates, being
transmembrane proteins containing repeated leucine-rich
motifs in their extracellular portions, similar to other pattern
recognition proteins and containing a cytoplasmic portion,
which is homologous to the IL-1 receptor, and hence could
trigger intracellular signaling pathways. Beutler’s group used
a genetics approach to identify TLR4 as the receptor for
lipopolysaccharide, providing a mechanism for innate
immune recognition of Gram-negative bacteria (Poltorak
et al., 1998). Our lab discovered that microbial lipoproteins
trigger host responses via TLR2, providing a mechanism
for innate immune recognition of both Gram-positive and
Gram-negative organisms. TLR2/6 heterodimers mediate the
response to diacylated lipoproteins, whereas TLR2/1 hetero-
dimers recognize triacylated lipoproteins (Brightbill et al.,
1999). For recognition of bacteria, the TLR system allows
recognition of several different ligands: TLR9 is activated by
unmethylated DNA sequences (CpG dinucleotides) found in
bacterial DNA (Hemmi et al., 2000) and TLR5 is activated by
bacterial flagellin (Hayashi et al., 2001). Specific TLRs are
involved in viral recognition: TLR3 is activated by viral-
derived double-stranded RNA (Alexopoulou et al., 2001),
and TLR7 and TLR8 by viral-derived single-stranded RNA
(Diebold et al., 2004; Figure 1).
The identification of TLR ligands made possible experi-
ments to investigate the functional role of TLRs in the innate
immune response. In Metchnikoff’s model of innate immu-
nity, recognition of the foreign invader was followed by
phagocytosis. It is required not only for physical destruction of
the pathogen but also allows for microbial antigen presenta-
tion to T cells in the context of major histocompatibility
complex molecules. TLRs can regulate phagocytosis either
through enhancing endosomal fusion with the lysosomal
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compartment (Blander and Medzhitov, 2004) or through
induction of a phagocytic gene program including multiple
scavenger receptors (Doyle et al., 2004).
TLRs also fulfill the final step of Metchnikoff’s innate
immunity—the induction of direct antimicrobial activity.
Activation of TLRs on monocytes triggers an antimicrobial
activity against intracellular bacteria such as Mycobacterium
tuberculosis, which in mice is nitric oxide dependent and in
humans is nitric oxide independent (Thoma-Uszynski et al.,
2001). In human monocytes, activation of TLRs induced an
antimicrobial activity against M. tuberculosis that was vitamin
D dependent (Liu et al., 2006). This pathway involved
induction of IL-15, leading to the induction of 25-hydroxy-
vitamin D3-1a-hydroxylase (CYP27b1), which converts 25D
into the active 1,25D form and upregulation/activation of the
vitamin D receptor (VDR; Krutzik et al., 2008). The activation
of the VDR triggered expression of the antimicrobial peptide
cathelicidin (Liu et al., 2006). Furthermore, the induction of
IL-1b and the VDR was required for upregulation of DEFB4
(Liu et al., 2009). The TLR-induced, vitamin D-dependent
antimicrobial pathway required induction of the antimicrobial
peptides cathelicidin and DEFB4 (Liu et al., 2007). The
vitamin D-dependent induction of antimicrobial peptides in
keratinocytes provides a mechanism for host defense in skin
(Schauber et al., 2007). In addition, activation of TLR3, 4, 7, 8,
and 9 leads to the induction of antiviral activity that is
dependent on Type I IFN secretion and involves specific
signaling pathways (Doyle et al., 2002).
The specific subcellular location of TLRs allows the
detection of microbes in distinct compartments. TLR3, 7, 8,
and 9 are located in endosomes, facilitating recognition of
RNA and DNA from microbial pathogens that reside in the
endocytic pathway. In contrast, TLR1, 2, 4, 5, and 6 are
located on the cell surface, providing the innate immune
system with the ability to recognize extracellular pathogens
or pathogen-associated molecular patterns released from
intracellular pathogens into the extracellular space. Other
PRRs are located in the cytoplasm, including the NLRs (NOD
(nucleotide-binding oligomerization domain)-like receptors),
which share homology to TLRs in containing leucine-rich
repeats. NOD1 and NOD2 recognize components of bac-
terial cells walls; specifically, NOD1 recognizes D-glutamyl-
meso-diaminopimelic acid (Girardin et al., 2003a) and
NOD2 senses muramyl dipeptide (Girardin et al., 2003b;
Inohara et al., 2003; Yang et al., 2007). Stimulation of NLRs
can activate a protein complex known as the inflammasome,
which by recruitment of caspase-1 leads to the proteolytic
cleavage and activation of IL-1b and other cytokines
(Martinon et al., 2009).
The discovery of NLRs has provided new insight into how
vaccine adjuvants work. It is tempting to speculate that the
utility of Bacillus Calmette-Guerin as an adjuvant is related to
its ability to activate NOD2. A key component of mycobac-
terial cell walls that confers adjuvant activity is the NOD2
agonist, muramyl dipeptide (Adam et al., 1974; Ellouz et al.,
1974). Muramyl dipeptide has been shown to be an effective
adjuvant for inducing both B-cell (Specter et al., 1978) and
T-cell (Sugimoto et al., 1978) responses. A muramyl dipep-
tide derivative has been explored as a possible immunothera-
peutic agent in the treatment of patients with osteosarcoma
(Kleinerman et al., 1992). Human monocytes with a func-
tional defect in NOD2 were found to have an 80% reduction
in cytokine response to M. tuberculosis (Ferwerda et al.,
2005). The vaccine adjuvant alum also activates the NLR
family, specifically the inflammasome component Nalp3
(Eisenbarth et al., 2008).
In addition to recognizing pathogen-associated molecular
patterns derived from microbes, PRRs of the innate immune
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Figure 1. Innate immune pathways of host defense in infection. Innate immune receptors reside in specific subcellular compartments, including cell
surface, cytoplasmic, and endocytic, providing the opportunity to recognize distinct microbial ligands. Some of the key pattern recognition receptors (PRRs)
involved in skin disease are shown, along with some of their microbial ligands, pathogen-associated molecular patterns (PAMPs). Included are various Toll-like
receptors (TLRs), nucleotide-binding oligomerization domain (NOD)-like receptors, and RIG-I-like receptors (RLRs). The activation of the innate immune system
leads to host immune responses that contribute to skin disease, including the differentiation of monocytes into macrophage subsets, antimicrobial activity,
dendritic cell differentiation, and T-cell differentiation. The key molecules involved in each process are shown. DC, dendritic cell; ds, double stranded;
LPS, lipopolysaccharide; MDP, muramyl dipeptide; MTP, muramyl tripeptide; ss, single stranded.
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system have been able to recognize danger-associated
molecular patterns (DAMPs) derived from injured or
damaged host cells (Martinon et al., 2006). Some DAMPs
include ATP, heparin sulfate, HMGB1, and S100 proteins.
The ability of the innate immune system to respond to
DAMPs contributes to tissue homeostasis and repair, but the
resulting inflammatory response can result in autoimmune
disease. For example, the recognition of uric acid crystals by
the NALP3 inflammasome contributes to the pathogenesis of
gout (Martinon et al., 2006). Of relevance to skin disease, the
inflammasome is activated in keratinocytes by UVB, as well
as chemical agents that induce irritant and contact dermatitis
(Watanabe et al., 2007).
The location of PRRs of the innate immune system in distinct
subcellular compartments facilitates detection of microbial
pathogens. At the same time, the location of these receptors
prevents activation by self-molecules that share homology to
microbial ligands, but do not normally access these locations.
However, when self-molecules gain access to these compart-
ments, autoimmune disease can be triggered (Martinon et al.,
2009; Davis et al., 2011). The innate system participates in
inflammation-associated carcinogenesis (Davis et al., 2011).
In the case of cell damage or death, the upregulation and
release of DAMPs provides one mechanism by which self-
molecules gain access to innate immune PRRs. A second
mechanism involves the transport of self-molecules across
membranes into compartments containing specific PRRs.
Michel Gilliet’s group has elucidated a transport mecha-
nism by which self-DNA is trafficked from an extracellular
location directly to endosomes, resulting in activation of the
innate immune system via TLR9 (Lande et al., 2007). This
transportation pathway may contribute to the pathogenesis of
psoriasis. First, the release of DNA from damaged cells
complexes with the antimicrobial peptide cathelicidin (aka
LL-37), which is known to be increased in psoriasis. These
DNA–cathelicidin complexes can then be transported across
cell membranes and then delivered into endosomes of
plasmacytoid dendritic cells, with subsequent activation of
TLR9 and release of type I IFNs known to trigger autoimmune
T-cell responses. Cathelicidin and anti-DNA/RNA antibodies
can transport both DNA and RNA into endosomes where
they activate relevant TLRs and contribute to the pathogen-
esis of autoimmune disease. These transportation pathways
may be beneficial to the host in combating microbial
infection, but can also contribute to tissue damage.
There are a wide range of inflammatory and infectious skin
diseases in which activation and/or dysregulation of PRR
signaling contributes to pathogenesis (Lai and Gallo, 2008;
Terhorst et al., 2010). The discovery of mammalian PRRs and
their biological roles has also provided an exciting new
opportunity to develop new pharmacological agents. We
have learned from the study of innate immunity that the drug
imiquimod, used to treat viral warts and actinic keratoses,
triggers TLR7 to induce a pro-inflammatory response (Hemmi
et al., 2002). It is tempting to speculate that other TLR and
NLR agonists may also serve as immunotherapeutic agents
and/or adjuvants for a new generation of vaccines. However,
there are circumstances in which blocking innate immune
responses may be beneficial, raising the possibility that
antagonists hold promise for a new class of anti-inflammatory
agents. Metchnikoff’s initial studies of the innate immune
systems of starfish and the water flea have enabled us to
develop insight into the human innate immune system and
provide the potential to intervene in human disease.
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